TrialJournal of the American College of Cardiology2022

Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.

Michael Böhm et al.PubMed ↗Publisher ↗

No numbers read from the abstract.